ACHE and early-onset autosomal dominant Alzheimer disease: The choice of AChE586-599 as a model peptide for amyloid assembly was guided by two criteria, which are the tractability of AChE586-599 assembly upon neutralization (AChE586-599 remains monomeric and random coil at acidic pH) and the involvement of AChE or related products in Alzheimer's disease and in the promotion of Aβ fibrilization [18], [23], [19], [20], [24].